CMAJ • January 16, 2007; 176 (2). First published December 19, 2006; doi:10.1503/cmaj.061020
© 2007 Canadian Medical Association or its licensors
All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association.
This Article
Right arrow Abstract
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Online Appendix
Right arrow Submit a response
Right arrow View responses
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ligthart, S.
Right arrow Articles by Brophy, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ligthart, S.
Right arrow Articles by Brophy, J. M.
Related Collections
Right arrow Ischemic heart disease
Right arrowRelated Articles

The cost-effectiveness of drug-eluting stents: a systematic review

Suzanne Ligthart, Floortje Vlemmix, Nandini Dendukuri and James M. Brophy

From the Department of Medical Technology Assessment (Ligthart, Vlemmix), University Medical Centre Nijmegen, Nijmegen, the Netherlands; the Technology Assessment Unit (Ligthart, Vlemmix, Dendukuri, Brophy), McGill University Health Centre, Montréal, Que.; and the Departments of Epidemiology and Biostatistics (Dendukuri, Brophy) and Medicine (Brophy), McGill University, Montréal, Que.


Figure 120
View larger version (24K):
[in this window]
[in a new window]

  		Fig. 1: Results of literature search for cost-effectiveness analyses comparing drug-eluting stents (DES) and bare-metal stents (BMS). See Methods for search terms. INAHTA = International Network of Agencies for Health Technology Assessment (www.inahta.org).

 

View this table:
[in this window]
[in a new window]

  		Table 1.

 

View this table:
[in this window]
[in a new window]

  		Table 2.

 

View this table:
[in this window]
[in a new window]

  		Table 3.

 

Figure 220
View larger version (25K):
[in this window]
[in a new window]

  		Fig. 2: Results of classification and regression tree (CART) analysis showing study characteristics that were predictive of the main outcome measure (study favoured use of drug-eluting stents). Percentages in parentheses indicate the proportion of studies that favoured widespread use. Quality = quality as determined with the use of the instrument in Appendix 1 (available online at www.cmaj.ca/cgi/content/full/176/2/199/DC1); sponsored = study directly sponsored by manufacturer of drug-eluting stent.